Latest Breaking News On - Alpha bronze - Page 5 : vimarsana.com

NLS Pharmaceutics AG: NLS Pharmaceutics Appoints Chad C Hellmann as Chief Financial Officer

ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

United statesAlex zwyerSubhasis royCindy rizzoPascal nigenVertebron incYachtstore ltdNuvision incPharmaceutics ltdExchange commissionWater incAlpha bronzeChief financial officerMarcus venturesChief executive officerRosebank capital partners

NLS Pharmaceutics Appoints Chad C Hellmann as Chief Financial Officer

NLS Pharmaceutics Appoints Chad C Hellmann as Chief Financial Officer
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.

United statesAlex zwyerSubhasis royCindy rizzoPascal nigenVertebron incYachtstore ltdNuvision incPharmaceutics ltdExchange commissionWater incAlpha bronzeChief financial officerMarcus venturesChief executive officerRosebank capital partners

NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy

Press release content from Accesswire. The AP news staff was not involved in its creation.

United statesAlex zwyerCindy rizzoPascal nigenExchange commissionAlpha bronzeWorld sleep congressPharmaceutics ltdEuropean sleep research society congressChief executive officerMazindol controlled releaseOrphan drug designationsClinical trials

NLS Pharmaceutics AG: NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience for the Treatment of Narcolepsy

60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022Nearly 90% of patients

United statesAlex zwyerCindy rizzoPascal nigenExchange commissionAlpha bronzeWorld sleep congressPharmaceutics ltdEuropean sleep research society congressChief executive officerMazindol controlled releaseOrphan drug designations

NLS Pharmaceutics AG: NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience Phase 2a Clinical Trial for Patients with Narcolepsy

Since the interim results were released in March, patient enrollment has nearly doubledOf the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing screeningNearly

United statesAlex zwyerCindy rizzoPascal nigenExchange commissionAlpha bronzeWorld sleep congressDrug administrationPharmaceutics ltdChief executive officerMazindol controlled releaseOrphan drug designations